<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34968008</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>14</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>25</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">2052-1707</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>10</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Pharmacology research &amp; perspectives</Title>
          <ISOAbbreviation>Pharmacol Res Perspect</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Molnupiravir: A new candidate for COVID-19 treatment.</ArticleTitle>
        <Pagination>
          <StartPage>e00909</StartPage>
          <MedlinePgn>e00909</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">e00909</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/prp2.909</ELocationID>
        <Abstract>
          <AbstractText>The novel coronavirus disease 2019 (COVID-19) emerged in late December 2019 in china and has rapidly spread to many countries around the world. The effective pharmacotherapy can reduce the mortality of COVID-19. Antiviral medications are the candidate therapies for the management of COVID-19. Molnupiravir is an antiviral drug with anti-RNA polymerase activity and currently is under investigation for the treatment of patients with COVID-19. This review focuses on summarizing published literature for the mechanism of action, safety, efficacy, and clinical trials of molnupiravir in the treatment of COVID-19 patients.</AbstractText>
          <CopyrightInformation>© 2021 The Authors. Pharmacology Research &amp; Perspectives published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley &amp; Sons Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Pourkarim</LastName>
            <ForeName>Fariba</ForeName>
            <Initials>F</Initials>
            <Identifier Source="ORCID">0000-0002-0026-9734</Identifier>
            <AffiliationInfo>
              <Affiliation>Student Research Committee, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pourtaghi-Anvarian</LastName>
            <ForeName>Samira</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Student Research Committee, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rezaee</LastName>
            <ForeName>Haleh</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Infectious Diseases and Tropical Medicine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Pharmacol Res Perspect</MedlineTA>
        <NlmUniqueID>101626369</NlmUniqueID>
        <ISSNLinking>2052-1707</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006898">Hydroxylamines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5CSZ8459RP</RegistryNumber>
          <NameOfSubstance UI="D003562">Cytidine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>YA84KI1VEW</RegistryNumber>
          <NameOfSubstance UI="C000656703">molnupiravir</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003562" MajorTopicYN="N">Cytidine</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006898" MajorTopicYN="N">Hydroxylamines</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
          <QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">COVID-19 treatment</Keyword>
        <Keyword MajorTopicYN="Y">EIDD-2801</Keyword>
        <Keyword MajorTopicYN="Y">MK-4482</Keyword>
        <Keyword MajorTopicYN="Y">antiviral drugs</Keyword>
        <Keyword MajorTopicYN="Y">molnupiravir</Keyword>
        <Keyword MajorTopicYN="Y">novel coronavirus disease 2019</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that there is no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>30</Day>
          <Hour>12</Hour>
          <Minute>52</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34968008</ArticleId>
        <ArticleId IdType="pmc">PMC8929331</ArticleId>
        <ArticleId IdType="doi">10.1002/prp2.909</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle. J Med Virol. 2020;92(4):401‐402.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7166628</ArticleId>
            <ArticleId IdType="pubmed">31950516</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223):497‐506.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7159299</ArticleId>
            <ArticleId IdType="pubmed">31986264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020;395(10223):507‐513.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7135076</ArticleId>
            <ArticleId IdType="pubmed">32007143</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020;395(10223):470‐473.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7135038</ArticleId>
            <ArticleId IdType="pubmed">31986257</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Baradaran H, Hamishehkar H, Rezaee H. NSAIDs and COVID‐19: a new challenging area. Pharm Sci. 2020;26(Suppl 1):S49‐S51.</Citation>
        </Reference>
        <Reference>
          <Citation>
World Health Organization
Coronavirus disease (COVID‐19) situation dashboard. CEST. Accessed December 23, 2021. https://covid19.who.int
</Citation>
        </Reference>
        <Reference>
          <Citation>
Rezaee H, Pourkarim F, Pourtaghi‐Anvarian S, et al. Drug‐drug interactions with candidate medications used for COVID‐19 treatment: an overview. Pharmacol Res Perspect. 2021;9(1).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7796804</ArticleId>
            <ArticleId IdType="pubmed">33421347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Corman VM, Landt O, Kaiser M. Detection of 2019 novel coronavirus (2019‐nCoV) by real‐time RT‐PCR. Eurosurveillance. 2020;25(3):2000045.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6988269</ArticleId>
            <ArticleId IdType="pubmed">31992387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rubin EJ, Baden LR, Morrissey S, Campion EW. Medical journals and the 2019‐nCoV outbreak. N Engl J Med. 2020;382(9):866.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31986242</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
National Center for Health Statistics, &amp; Centers for Disease Control and Prevention
. COVID‐19 data from the National Center for Health Statistics. 2020. Accessed April 1, 2020. https://www.cdc.gov/coronavirus/2019‐ncov/symptoms‐testing/symptoms.html
</Citation>
        </Reference>
        <Reference>
          <Citation>
Lechien JR, Chiesa‐Estomba CM, Hans S, Barillari MR, Jouffe L, Saussez S. Loss of smell and taste in 2013 European patients with mild to moderate COVID‐19. Ann Intern Med. 2020;173(8):672‐675.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7505100</ArticleId>
            <ArticleId IdType="pubmed">32449883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
World Health Organization
Coronavirus disease (COVID‐19) weekly epidemiological update. 2020. Accessed August 24, 2020. https://www.who.int/docs/default‐source/coronaviruse/situation‐reports/20200824‐weekly‐epi‐update.pdf?sfvrsn=806986d1_4
</Citation>
        </Reference>
        <Reference>
          <Citation>
Gorbalenya AE, Baker SC, Baric RS, Coronaviridae Study Group of the International Committee on Taxonomy of Viruses
, et al. The species severe acute respiratory syndrome‐related coronavirus: classifying 2019‐nCoV and naming it SARS‐CoV‐2. Nat Microbiol. 2020;5(4):536‐544.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7095448</ArticleId>
            <ArticleId IdType="pubmed">32123347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nouri‐Vaskeh M, Kalami N, Zand R, et al. Comparison of losartan and amlodipine effects on the outcomes of patient with COVID‐19 and primary hypertension: a randomised clinical trial. Int J Clin Pract. 2021;75(6):e14124.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7995089</ArticleId>
            <ArticleId IdType="pubmed">33650197</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ciotti M, Angeletti S, Minieri M. COVID‐19 outbreak: an overview. Chemotherapy. 2019;64(5‐6):215‐223.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7179549</ArticleId>
            <ArticleId IdType="pubmed">32259829</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Abdelnabi R, Foo CS, Kaptein SJ, et al. The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS‐CoV‐2 hamster infection model. EBioMedicine. 2021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8461366</ArticleId>
            <ArticleId IdType="pubmed">34571361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Toots M, Yoon J‐J, Hart M, Natchus MG, Painter GR, Plemper RK. Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD‐2801 in the ferret model. Transl Res. 2020;218:16‐28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7568909</ArticleId>
            <ArticleId IdType="pubmed">31945316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Vicenti I, Zazzi M, Saladini F. SARS‐CoV‐2 RNA‐dependent RNA polymerase as a therapeutic target for COVID‐19. Expert Opin Ther Pat. 2021;31(4):325‐337.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7938656</ArticleId>
            <ArticleId IdType="pubmed">33475441</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Paymode DJ, Vasudevan N, Ahmad S, et al. Toward a practical, two‐step process for molnupiravir from cytidine. Org Process Res Dev. 2021;25:1822‐1830.</Citation>
        </Reference>
        <Reference>
          <Citation>
Abdelnabi R, Foo CS, Kaptein SJ, et al. The combined treatment of Molnupiravir and Favipiravir results in a marked potentiation of efficacy in a SARS‐CoV2 hamster infection model through an increased frequency of mutations in the viral genome. bioRxiv. 2021; 2020–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8461366</ArticleId>
            <ArticleId IdType="pubmed">34571361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Li W, Moore MJ, Vasilieva N, et al. Angiotensin‐converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450‐454.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7095016</ArticleId>
            <ArticleId IdType="pubmed">14647384</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jia HP, Look DC, Shi L, et al. ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. J Virol. 2005;79(23):14614‐14621.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1287568</ArticleId>
            <ArticleId IdType="pubmed">16282461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Grass GD, Toole BP. How, with whom and when: an overview of CD147‐mediated regulatory networks influencing matrix metalloproteinase activity. Biosci Rep. 2016;36(1):e00283.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4718507</ArticleId>
            <ArticleId IdType="pubmed">26604323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Duffy S, Shackelton LA, Holmes EC. Rates of evolutionary change in viruses: patterns and determinants. Nat Rev Genet. 2008;9(4):267‐276.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18319742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Khadke S, Ahmed N, Ahmed N, et al. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID‐19: a review of the phases of illness and therapeutic agents. Virol J. 2020;17(1):1‐8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7558250</ArticleId>
            <ArticleId IdType="pubmed">33059711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wahl A, Gralinski LE, Johnson CE, et al. SARS‐CoV‐2 infection is effectively treated and prevented by EIDD‐2801. Nature. 2021;591(7850):451‐457.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7979515</ArticleId>
            <ArticleId IdType="pubmed">33561864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Thakur S, Sarkar B, Ansari AJ, et al. Exploring the magic bullets to identify Achilles’ heel in SARS‐CoV‐2: delving deeper into the sea of possible therapeutic options in Covid‐19 disease: an update. Food Chem Toxicol. 2021;147:111887.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7694479</ArticleId>
            <ArticleId IdType="pubmed">33253764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Padhi AK, Shukla R, Saudagar P, Tripathi T. High‐throughput rational design of the remdesivir binding site in the RdRp of SARS‐CoV‐2: implications for potential resistance. Iscience. 2021;24(1):101992.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7807151</ArticleId>
            <ArticleId IdType="pubmed">33490902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Painter WP, Holman W, Bush JA, et al. Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad‐spectrum oral antiviral agent with activity against SARS‐CoV‐2. Antimicrob Agents Chemother. 2021;65(5).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8092915</ArticleId>
            <ArticleId IdType="pubmed">33649113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Painter WP, Holman W, Bush JA, et al. Human safety, tolerability, and pharmacokinetics of a novel broad‐spectrum oral antiviral compound, molnupiravir, with activity against SARS‐CoV‐2. medRxiv. 2020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8092915</ArticleId>
            <ArticleId IdType="pubmed">33649113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Singh AK, Singh A, Singh R, Misra A. Molnupiravir in COVID‐19: a systematic review of literature. Diabetes Metab Syndr. 2021;15(6):102329.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8556684</ArticleId>
            <ArticleId IdType="pubmed">34742052</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Menéndez‐Arias L. Decoding molnupiravir‐induced mutagenesis in SARS‐CoV‐2. J Biol Chem. 2021;297(1):100867.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8188802</ArticleId>
            <ArticleId IdType="pubmed">34118236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kumar D, Trivedi N. Disease‐drug and drug‐drug interaction in COVID‐19: risk and assessment. Biomed Pharmacother. 2021;139:111642.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8078916</ArticleId>
            <ArticleId IdType="pubmed">33940506</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Miller SR, McGrath ME, Zorn KM, Ekins S, Wright SH, Cherrington NJ. Remdesivir and EIDD‐1931 Interact with human equilibrative nucleoside transporters 1 and 2: implications for reaching SARS‐CoV‐2 viral sanctuary sites. Mol Pharmacol. 2021;100(6):548‐557.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8626781</ArticleId>
            <ArticleId IdType="pubmed">34503974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cox RM, Wolf JD, Plemper RK. Therapeutically administered ribonucleoside analogue MK‐4482/EIDD‐2801 blocks SARS‐CoV‐2 transmission in ferrets. Nat Microbiol. 2021;6(1):11‐18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7755744</ArticleId>
            <ArticleId IdType="pubmed">33273742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rosenke K, Hansen F, Schwarz B, et al. Orally delivered MK‐4482 inhibits SARS‐CoV‐2 replication in the Syrian hamster model. Nat Commun. 2021;12(1):1‐8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8052374</ArticleId>
            <ArticleId IdType="pubmed">33863887</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
